BYAH
Park Ha Biological·NASDAQ
--
--(--)
--
--(--)
BYAH fundamentals
During FY 2025, Park Ha Biological (BYAH) reported revenue of 2.52M, a YoY change of 6.00%. Net income was -24.36M, a YoY change of -5191.25%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
FY,2022 | H1,2023 | FY,2023 | H1,2024 | FY,2024 | H1,2025 | FY,2025 | TTM |
|---|
Start Date | Nov 1, 2021 | Nov 1, 2022 | Nov 1, 2022 | Nov 1, 2023 | Nov 1, 2023 | Nov 1, 2024 | Nov 1, 2024 | -- |
End Date | Oct 31, 2022 | Apr 30, 2023 | Oct 31, 2023 | Apr 30, 2024 | Oct 31, 2024 | Apr 30, 2025 | Oct 31, 2025 | -- |
Fiscal Year-End | Oct 31 | Oct 31 | Oct 31 | Oct 31 | Oct 31 | Oct 31 | Oct 31 | -- |
Revenue | 1.92M -- | 1.37M -- | 2.46M +28.12% | 852.93K -37.81% | 2.38M -3.14% | 1.24M +45.29% | 2.52M +6.00% | 2.52M -- |
Sales and Services Revenue | 1.92M -- | 1.37M -- | 2.46M +28.12% | 852.93K -37.81% | 2.38M -3.14% | 1.24M +45.29% | 2.52M +6.00% | 2.52M -- |
Cost of Revenue | 509.16K -- | 125.02K -- | 310.99K -38.92% | 98.11K -21.52% | 195.34K -37.19% | 58.50K -40.37% | 142.53K -27.04% | 142.53K -- |
Cost of Goods and Services | 509.16K -- | -- -- | 310.99K -38.92% | 98.11K -- | 195.34K -37.19% | 58.50K -40.37% | 142.53K -27.04% | 142.53K -- |
Gross Profit | 1.41M -- | 1.25M -- | 2.15M +52.32% | 754.82K -39.45% | 2.19M +1.79% | 1.18M +56.42% | 2.38M +8.95% | 2.38M -- |
Operating Expenses | 1.21M -- | 571.72K -- | 967.56K -20.25% | 662.45K +15.87% | 1.39M +43.95% | 20.90M +3054.39% | 26.53M +1804.88% | 26.53M -- |
Selling, General and Administrative Expenses | 1.15M -- | 438.22K -- | 784.57K -31.54% | 609.83K +39.16% | 1.18M +49.91% | 20.86M +3321.00% | 26.11M +2119.79% | 26.11M -- |
Selling and Marketing Expenses | 438.60K -- | -- -- | 299.62K -31.69% | 157.73K -- | 361.33K +20.60% | 229.78K +45.67% | 625.29K +73.05% | 625.29K -- |
General and Administrative Expenses | 707.49K -- | -- -- | 484.95K -31.45% | 452.10K -- | 814.86K +68.03% | 20.63M +4463.73% | 25.48M +3027.36% | 25.48M -- |
Research and Development Expenses | 60.67K -- | 17.17K -- | 30.88K -49.10% | 20.08K +16.98% | 36.71K +18.89% | 26.09K +29.90% | 238.18K +548.76% | 238.18K -- |
Loss on Bad Debts | 6.44K -- | -- -- | 152.11K +2261.19% | 32.54K -- | 179.90K +18.27% | 7.88K -75.77% | 184.20K +2.39% | 184.20K -- |
Other Operating Expenses | -- -- | 116.33K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Income | 197.02K -- | 674.85K -- | 1.18M +499.19% | 92.37K -86.31% | 793.71K -32.77% | -19.72M -21444.62% | -24.15M -3142.52% | -24.15M -- |
Non-Operating Income (Loss) | -7.01K -- | 2.65K -- | 1.01K +114.47% | 918 -65.38% | -293 -128.87% | 58.55K +6277.89% | 64.79K +22213.99% | 64.79K -- |
Other Non-Operating Income (Loss) | -7.08K -- | 2.04K -- | -575 +91.88% | -133 -106.53% | -1.08K -87.13% | 58.15K +43824.06% | 58.74K +5558.92% | 58.74K -- |
Net Interest Expense | -69 -- | -616 -- | -1.59K -2204.35% | -1.05K -70.62% | -783 +50.75% | -396 +62.32% | -6.06K -673.44% | -6.06K -- |
Interest Expense | 194 -- | -- -- | 0 -100.00% | 0 -- | 0 -- | 20 -- | 41 -- | 41 -- |
Interest Income | 263 -- | 616 -- | 1.59K +504.56% | 1.05K +70.62% | 783 -50.75% | 416 -60.42% | 6.10K +678.67% | 6.10K -- |
Pretax Income From Continuing Operations | 190.01K -- | 677.50K -- | 1.18M +521.85% | 93.29K -86.23% | 793.42K -32.85% | -19.66M -21171.81% | -24.08M -3135.48% | -24.08M -- |
Income Tax Expense | -1.29K -- | 177.71K -- | 329.53K +25684.39% | 44.39K -75.02% | 314.86K -4.45% | 178.95K +303.16% | 280.65K -10.87% | 280.65K -- |
Current Income Tax | 0 -- | -- -- | 363.26K -- | 51.18K -- | 336.32K -7.42% | 180.94K +253.54% | 307.32K -8.62% | 307.32K -- |
Deferred Income Tax | -1.29K -- | -- -- | -33.74K -2519.33% | -6.79K -- | -21.46K +36.38% | -1.99K +70.66% | -26.67K -24.25% | -26.67K -- |
Net Income | 191.30K -- | 499.80K -- | 852.04K +345.40% | 48.90K -90.22% | 478.56K -43.83% | -19.84M -40664.40% | -24.36M -5191.25% | -24.36M -- |
Net Income Attributable to Owners of the Company | 191.30K -- | 499.80K -- | 852.04K +345.40% | 48.90K -90.22% | 478.56K -43.83% | -19.84M -40664.40% | -24.36M -5191.25% | -24.36M -- |
Net Income Attributable to Common Stockholders | 191.30K -- | 499.80K -- | 852.04K +345.40% | 48.90K -90.22% | 478.56K -43.83% | -19.84M -40664.40% | -24.36M -5191.25% | -24.36M -- |
Other Comprehensive Income | 3.01K -- | 9.56K -- | -28.11K -1032.68% | 6.13K -35.86% | 14.55K +151.76% | -10.00K -262.98% | -7.02K -148.27% | -7.02K -- |
Total Comprehensive Income | 194.31K -- | 509.36K -- | 823.93K +324.02% | 55.03K -89.20% | 493.11K -40.15% | -19.85M -36160.68% | -24.37M -5042.44% | -24.37M -- |
Total Comprehensive Income Attributable to Owners of the Company | 194.31K -- | 509.36K -- | 823.93K +324.02% | 48.90K -90.40% | 493.11K -40.15% | -19.84M -40664.40% | -24.37M -5042.44% | -24.37M -- |
Basic EPS | 0.01 -- | 0.02 -- | 1.7 +16900.00% | 0 -100.00% | 0.96 -43.53% | -0.74 -- | -41.38 -4410.42% | -41.38 -- |
Basic EPS from Continuing Operations | 0.01 -- | -- -- | 1.7 +16900.00% | 0 -- | 0.96 -43.53% | -0.74 -- | -41.38 -4410.42% | -41.38 -- |
Diluted EPS | 0.01 -- | 0.02 -- | 1.7 +16900.00% | 0 -100.00% | 0.96 -43.53% | -0.74 -- | -41.38 -4410.42% | -41.38 -- |
Diluted EPS from Continuing Operations | 0.01 -- | -- -- | 1.7 +16900.00% | 0 -- | 0.96 -43.53% | -0.74 -- | -41.38 -4410.42% | -41.38 -- |
You can ask Aime
What is the market's earnings forecast for Park Ha Biological next quarter?What were the key takeaways from Park Ha Biological's earnings call?What is Park Ha Biological's latest dividend and current dividend yield?What does Park Ha Biological do and what are its main business segments?Did Park Ha Biological beat or miss consensus estimates last quarter?What factors drove the changes in Park Ha Biological's revenue and profit?What is the revenue and EPS growth rate for Park Ha Biological year over year?What guidance did Park Ha Biological's management provide for the next earnings period?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
